On a scale of 0 to 100, Evofem Biosciences holds a performance score of 2. The firm shows a Beta (market volatility) of 1.37, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Evofem Biosciences will likely underperform. Please check Evofem Biosciences' treynor ratio, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Evofem Biosciences' price patterns will revert.
Risk-Adjusted Performance
Weak
Weak
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Evofem Biosciences are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating technical and fundamental indicators, Evofem Biosciences displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Begin Period Cash Flow
72.3 M
Total Cashflows From Investing Activities
-2.7 M
Evofem
Evofem Biosciences Relative Risk vs. Return Landscape
If you would invest 1.00 in Evofem Biosciences on October 17, 2025 and sell it today you would lose (0.08) from holding Evofem Biosciences or give up 8.0% of portfolio value over 90 days. Evofem Biosciences is currently generating 0.3616% in daily expected returns and assumes 10.3003% risk (volatility on return distribution) over the 90 days horizon. In different words, 92% of pink sheets are less volatile than Evofem, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Given the investment horizon of 90 days Evofem Biosciences is expected to generate 14.6 times more return on investment than the market. However, the company is 14.6 times more volatile than its market benchmark. It trades about 0.04 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.16 per unit of risk.
Evofem Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evofem Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Evofem Biosciences, and traders can use it to determine the average amount a Evofem Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0351
High Returns
Best Equity
Good Returns
Average Returns
Small Returns
EVFM
Cash
Small Risk
Average Risk
High Risk
Huge Risk
Negative Returns
Based on monthly moving average Evofem Biosciences is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Evofem Biosciences by adding it to a well-diversified portfolio.
Evofem Biosciences Fundamentals Growth
Evofem Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Evofem Biosciences, and Evofem Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evofem Pink Sheet performance.
By examining Evofem Biosciences' fundamental ratios, stakeholders can obtain critical insights into Evofem Biosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Evofem Biosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in womens sexual and reproductive health. Evofem Biosciences, Inc. is headquartered in San Diego, California. Evofem Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 119 people.
Things to note about Evofem Biosciences performance evaluation
Checking the ongoing alerts about Evofem Biosciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Evofem Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Evofem Biosciences had very high historical volatility over the last 90 days
Evofem Biosciences has some characteristics of a very speculative penny stock
Evofem Biosciences has a very high chance of going through financial distress in the upcoming years
Evofem Biosciences currently holds 125.74 M in liabilities with Debt to Equity (D/E) ratio of 8.72, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evofem Biosciences has a current ratio of 0.16, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Evofem Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Evofem Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Evofem Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Evofem to invest in growth at high rates of return. When we think about Evofem Biosciences' use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 8.24 M. Net Loss for the year was (205.19 M) with profit before overhead, payroll, taxes, and interest of 4.19 M.
Evofem Biosciences currently holds about 19.89 M in cash with (146.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Evaluating Evofem Biosciences' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Evofem Biosciences' pink sheet performance include:
Analyzing Evofem Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evofem Biosciences' stock is overvalued or undervalued compared to its peers.
Examining Evofem Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Evofem Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evofem Biosciences' management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of Evofem Biosciences' pink sheet. These opinions can provide insight into Evofem Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Evofem Biosciences' pink sheet performance is not an exact science, and many factors can impact Evofem Biosciences' pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Other Information on Investing in Evofem Pink Sheet
Evofem Biosciences financial ratios help investors to determine whether Evofem Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evofem with respect to the benefits of owning Evofem Biosciences security.